A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer

被引:9
|
作者
Poel, Dennis [1 ,2 ]
Gootjes, Elske C. [1 ,2 ]
Bakkerus, Lotte [1 ,2 ]
Trypsteen, Wim [3 ,4 ]
Dekker, Henk [1 ]
van der Vliet, Hans J. [1 ]
van Grieken, Nicole C. T. [5 ]
Verhoef, Cornelis [6 ]
Buffart, Tineke E. [1 ,7 ]
Verheul, Henk M. W. [1 ,2 ]
机构
[1] VU Univ Med Ctr Amsterdam, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands
[2] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands
[3] Univ Ghent, Fac Med & Hlth Sci, HIV Cure Res Ctr, Dept Internal Med & Pediat, Ghent, Belgium
[4] Ghent Univ Hosp, Ghent, Belgium
[5] VU Univ Med Ctr Amsterdam, Canc Ctr Amsterdam, Dept Pathol, Amsterdam UMC, Amsterdam, Netherlands
[6] Erasmus MC Canc Inst, Div Surg Oncol, Dept Surg, Rotterdam, Netherlands
[7] Dept Gastrointestinal Oncol, Amsterdam, Netherlands
来源
CANCER MEDICINE | 2020年 / 9卷 / 20期
关键词
chemotherapy; colorectal cancer; metastases; miRNA; response prediction; serum; FOLFIRI PLUS BEVACIZUMAB; 1ST-LINE TREATMENT; CIRCULATING MICRORNAS; FRESH-FROZEN; OPEN-LABEL; EXPRESSION; FLUOROURACIL; CHEMOTHERAPY; COMBINATION; LEUCOVORIN;
D O I
10.1002/cam4.3371
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Palliative systemic therapy is currently standard of care for patients with extensive metastatic colorectal cancer (mCRC). A biomarker predicting chemotherapy benefit which prevents toxicity from ineffective treatment is urgently needed. Therefore, a previously developed tissue-derived microRNA profile to predict clinical benefit from chemotherapy was evaluated in tissue biopsies and serum from patients with mCRC. Methods Samples were prospectively collected from patients (N = 132) who were treated with capecitabine or 5-FU/LV with oxaliplatin +/- bevacizumab. Response evaluation was performed according to RECIST 1.1 after three or four cycles, respectively. Baseline tissue and serum miRNAs expression levels of miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p, and miR-98-5p were quantified with RT-qPCR and droplet digital PCR, respectively. Combined predictive performance of selected variables was tested using logistic regression analysis. Results From 132 patients, 81 fresh frozen tissue biopsies from metastases and 93 serum samples were available. Based on expression levels of miRNAs in tissue, progressive disease could be predicted with an AUC of 0.85 (95% CI:0.72-0.91) and response could be predicted with an AUC of 0.70 (95% CI:0.56-0.80). This did not outperform clinical parameters alone (respectivelyP = .14 andP = .27). Expression levels of miR-92a-3p and miR-98-5p in serum significantly improved the predictive value of clinical parameters for response to chemotherapy (AUC 0.74, 95% CI:0.64-0.84,P = .003) in this cohort. Conclusions The additive predictive value to clinical parameters of the tissue-derived six miRNA profile for clinical benefit could not be validated in patients with mCRC treated with first-line systemic therapy. Although miR-92a-3p and miR-98-5p serum levels improved the predictive value of clinical parameters, it remained insufficient for clinical decision-making.
引用
收藏
页码:7558 / 7571
页数:14
相关论文
共 50 条
  • [41] Analysis of Adverse Events of Bevacizumab-containing Systemic Chemotherapy for Metastatic Colorectal Cancer in Japan
    Isobe, Taichi
    Uchino, Keita
    Makiyama, Chinatsu
    Ariyama, Hiroshi
    Arita, Shuji
    Tamura, Shingo
    Komoda, Masato
    Kusaba, Hitoshi
    Shirakawa, Tsuyoshi
    Esaki, Taito
    Mitsugi, Kenji
    Takaishi, Shigeo
    Akashi, Koichi
    Baba, Eishi
    ANTICANCER RESEARCH, 2014, 34 (04) : 2035 - 2040
  • [42] The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer
    Diaz-Serrano, Asuncion
    Riesco-Martinez, Maria C.
    Garcia-Carbonero, Rocio
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (06) : 585 - 595
  • [43] The Clinical Significance of MiR-429 as a Predictive Biomarker in Colorectal Cancer Patients Receiving 5-Fluorouracil Treatment
    Dong, Sheng-jian
    Cai, Xiao-jun
    Li, Shu-jin
    MEDICAL SCIENCE MONITOR, 2016, 22 : 3352 - 3361
  • [44] Understanding microRNA-Mediated Chemoresistance in Colorectal Cancer Treatment
    Valenzuela, Guillermo
    Contreras, Hector R.
    Marcelain, Katherine
    Burotto, Mauricio
    Gonzalez-Montero, Jaime
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (03)
  • [45] FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
    Antoniotti, Carlotta
    Vetere, Guglielmo
    Cremolini, Chiara
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
  • [46] Treatment Holidays for Patients With Metastatic Colorectal Cancer
    Kasi, Pashtoon Murtaza
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (33) : 3656 - +
  • [47] A systematic review and network meta-analysis of RCTs: The effect of systemic immunotherapies on treatment outcomes and quality of life in patients with metastatic colorectal cancer
    Zhu, Yiying
    Fu, Xiangwei
    Dai, Yonggang
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2025,
  • [48] Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer
    Nygard, Sune Boris
    Christensen, Ib Jarle
    Nielsen, Signe Lykke
    Nielsen, Hans Jorgen
    Brunner, Nils
    Spindler, Karen-Lise Garm
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2014, 49 (01) : 84 - 91
  • [49] Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients
    Landre, Thierry
    Maillard, Emilie
    Taleb, Cherifa
    Ghebriou, Djamel
    Des Guetz, Gaetan
    Zelek, Laurent
    Aparicio, Thomas
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2018, 33 (08) : 1125 - 1130
  • [50] Irinotecan-Cetuximab-Bevacizumab as a Salvage Treatment in Heavily Pretreated Metastatic Colorectal Cancer Patients: A Retrospective Observational Study
    Feliu Batlle, J.
    Cuadrado, E.
    Castro, J.
    Caldes, T.
    Belda, C.
    Sastre, J.
    Barriuso, J.
    Martinez Marin, V.
    Diaz-Rubio, E.
    Gonzalez-Baron, M.
    CHEMOTHERAPY, 2011, 57 (02) : 138 - 144